Institut Pasteur

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Theravectys

Universite Paris 7

Other

Institute Pasteur

Institut National De La Santéde La Recherche Médicale

Centre National De La Recherche Scientifique-cnrs

Universite Paris Vii

Pierre Charneau

Véronique Zennou

Hüseyin Firat

Philippe Despres

Frédéric Tangy

Francoise Pflumio

Frederic Philippe Coutant

Anne-Sophie Beignon

Luc Montagnier

Denise Guetard

Marie-Pascale Frenkiel

Karine Courbeyrette

Aride Sirven

Anne Dubart

Jacqueline Donjon De Saint-Martin

Philippe Souque

Caroline Quillent

Andrew Borman

Chantal Combredet

Sylvie Paulous

Yves Jacob

Jean-Claude Manuguerra

Fran&ccedil;ois Clavel

Nicolas Escriou

Sylvie Van Der Werf

Jacques Cohen

François Clavel

Anne Dubart Kupperschmitt

Aude Sirven

V&eacute;ronique Zennou

Sylvie Gerbaud

Monique Martin

Jean-François Delagneau

Ana Maria Burguiere

Valérie Lorin

Jean-Michel Betton

Benoît Callendret

Bernadette Crescenzo-Chaigne

Saliha Azebi

Melissanne De Wispelaere

Francois Clavel

Cecile Bauche

Jacques H M Cohen

Frederik Kunst

Anne-Claire Brehin

V&eacute;ronique Obry

Catherine Blanc

Elisabeth Dam

Esther Race

H&uuml;seyin Firat

Valerie Marechal

Frederick Kunst

Rogerio Amino

Thi-Lan Tran

Frederic Tangy

Frederik Inst Pasteur Bureau Des Brevets Et Inventions Kunst

Françoise Pflumio

Frederik Institut Pasteur Kunst

Valérie Marechal

Philippe Després

Frédéric Philippe Coutant

Fréderic Philippe Coutant

Anne-Claire Julie Brehin

The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.

Lentiviral vector-based Japanese encephalitis immunogenic composition

The invention relates toantigenic polypeptides identified through the use of a specifically devised functional immunization screening assay. In particular, the invention relates to antigenic polypeptides of malaria parasites wherein said antigenic polypeptides that exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge bysporozoites. The invention relates to a combination of compounds, comprising at least 2 distinct active ingredients wherein each active ingredient consists of an antigenic polypeptide of aparasite, a polynucleotide encoding the antigenic polypeptide, or a vector, in particular a viral vector, especially a lentiviral vector, expressing such antigenic polypeptide of aparasite, wherein one antigenic polypeptide is the circumsporozoite protein (CSP) or a polypeptidic derivative thereof and another antigenic polypeptide is either protein Ag40 (11-09) or protein Ag45 (11-10).

Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host

The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

The invention relates to lentiviral vector particles pseudotyped with a determined heterologous viral envelope protein or viral envelope proteins originating from a RNA virus and which comprise in its genome at least one recombinant polynucleotide encoding at least one polypeptide(s) carrying epitope(s) of an antigen of aparasite capable of infecting a mammalian host. The lentiviral vector particles are used in order to elicit an immunological response against malaria parasites.

Lentiviral vector based immunological compounds against malaria

The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.

Use of non-subtype B gag proteins for lentiviral packaging

The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.

Cells and methodology to generate non-segmented negative-strand RNA  viruses

The present invention concerns wild-strains of Chikungunya virus isolated from patients exhibiting severe forms of infection and stemming from a human arbovirosis epidemy. The present invention also concerns polypeptide sequences and fragment thereof derived from their genome, the polynucleotide encoding same and their use as diagnostic products, as vaccine and/or as immunogenic compositions.

Isolated and purified strains of Chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof

The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.

Lentiviral gene transfer vectors and their medicinal applications

Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae infection in a sensitive species.

Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.

Lentiviral vectors for the preparation of immunotherapeutical compositions

Cells and methodology to generate non-segmented negative-strand RNA viruses

Growing community of inventors

Paris, France

Pierre Charneau